BEGIN:VCALENDAR VERSION:2.0 PRODID:-//KESHO - ECPv6.15.20//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:KESHO X-ORIGINAL-URL:https://kesho-kenya.org X-WR-CALDESC:Events for KESHO REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:Africa/Nairobi BEGIN:STANDARD TZOFFSETFROM:+0300 TZOFFSETTO:+0300 TZNAME:EAT DTSTART:20150101T000000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210506T190000 DTEND;TZID=Africa/Nairobi:20210506T203000 DTSTAMP:20260424T235428 CREATED:20210810T102601Z LAST-MODIFIED:20220314T124351Z UID:5238-1620327600-1620333000@kesho-kenya.org SUMMARY:Optimizing Cancer Research in Kenya DESCRIPTION:[vc_row][vc_column][vc_column_text] \nModerator: Dr. Veronica Manduku\, Radiologist at Kenya Medical Research Institute \nSponsor: Roche \nPresenters: \n\nProf. Mansour Saleh\, Chair\, Department of hematology and oncology and consultant medical oncologist\, Aga Khan University Hospital\, Nairobi.\nProf. Fredrick Chite\, CEO/Executive Director of International Cancer Institute (ICI)\nProf. N.A.O. Abinya\, Medical Oncologist\, the Nairobi Hospital and GIPAP Physician\nDr. Robai Gakunga\, Independent Research Scientist\, USIU-Africa\n\nCancer research in Kenya is mainly in the universities and is more of epidemiological studies with limited clinical research. Considering the increasing demand for cancer research in Kenya\, there is a need to develop a curriculum\, build capacity and create infrastructures to support quality research. Many drugs used in Africa are not tested in Africa\, despite research showing variations in transcriptomics for example in triple-negative breast cancer for different races. Cancer research requires a multidisciplinary approach (MDT). Funding is a major challenge in cancer research. Additionally\, managing clinical practice and research becomes difficult in Kenya where clinicians are expected to spend 100% of the time in practice\, unlike in the USA\, where there is the flexibility of working hours. In the USA\, a clinician can spend 50% of the time in clinical practice and 50% in research. In Kenya\, the workloads for doctors\, clinicians\, and lecturers are overwhelming\, with no protected time for research from the institutions. In-Africa collaborations\, as opposed to Africa-America\, and networks between clinicians\, consultants\, academic institutions\, and government agencies\, would greatly help to generate local data. Data sharing and Trust is needed and the ability to work together to accomplish a goal. The University of Nairobi has an oncology training fellowship that is helping to build capacity in the region. Commitment in science for clinicians as well as developing and reviewing protocols collectively is necessary. Considering the high cost of cancer drugs\, cancer clinical trials should seek collaborations with pharmaceutical companies. Community and patient engagement are important in clinical trials. There is a need for a data repository and registries. There is an epidemiological registry in breast cancer collected at Kenya National Hospital in collaboration with Roche. Collaborations will facilitate sharing of human resources\, infrastructure\, and samples. The literature review is equally important. The exchange program for fellows helps with gaining experience to see what other researchers are doing. Scientists are encouraged to apply for research grants\, however small. There is a need for seed funds for young investigators. Government-government collaborations are also encouraged. Research governance is necessary. in lobbying government funding\, in priority areas including the most prevalent cancers (breast cancer in women\, prostate cancer in men). \n. \n[/vc_column_text] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/optimizing-cancer-research-in-kenya/ CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210811_132731.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210429T190000 DTEND;TZID=Africa/Nairobi:20210429T203000 DTSTAMP:20260424T235428 CREATED:20210810T095134Z LAST-MODIFIED:20211024T153933Z UID:5833-1619722800-1619728200@kesho-kenya.org SUMMARY:Testicular Cancer DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Peter Oyiro\, Medical Oncologist Kenyatta National Hospital Teaching and Referral Hospital \nSponsor: Glenmark \nPresenters: \n\nDr. Amina H. Kidee\, Medical Oncologist Aga Khan University Hospital\nDr. Carnjini Yogeswaran\, Consultant Urological Surgeon\, Aga Khan University Hospital\n\nTesticular cancer (TC) accounts for less than 1% of adult neoplasms and 5% of urological tumors.  It’s the most commonly diagnosed cancer in young men (20-34 years)\, and the incidence is increasing in industrialized countries.\, but there is a need for local data to determine incidence in Africa. It is predicted that the survival rate in Kenya is low since the disease is not diagnosed early.  The risk factors for TC oncogenesis include cryptorchidism\, history of subfertility\, contralateral history of testicular cancer\, history of germ cell neoplasm in situ\, family history of TC\, race\, age\, and HIV. Individuals at high risk should be informed about the importance of physical self-examination. WHO classification of TC is based on the tumor origin\, and the presentation may be localized or disseminated. Diagnosis is by history\, examination\, imaging\, and serum tumor markers used for prognosis and staging.  Transcrotal ultrasound with Doppler is performed to confirm a testicular mass\, to determine whether a mass is intra or extra testicular\, and to explore the contralateral testis. Transscrotal biopsies of the testes should not be performed because of the risk of tumor cells seeding of the inguinal and pelvic lymphatic drainage. The biopsy is also of limited value because testicular germ cell tumors are heterogeneous. Management of the disease requires an integrated multidisciplinary team (MDT). Removal of the entire organ is necessary to properly identify the histologic type(s) present and to select the appropriate therapy. Radical inguinal Orchidectomy is the standard of care and involves the division of the spermatic cord at the internal inguinal ring. The scrotal approach should be avoided. Chemotherapy should be initiated prior to orchidectomy where applicable\, to control the disease and stabilize the patient. Testis sparing surgery aims to preserve fertility and hormonal functions. Patients should be counseled and be informed of the risk of local recurrence which is 8%. The testicular prosthesis should be offered to all patients undergoing unilateral or bilateral orchidectomy. It can be inserted at orchidectomy or subsequently. Contralateral testicular biopsy should be offered to high-risk patients. Semen abnormalities occur in 24-50% of TC patients even prior to orchidectomy. Additionally\, chemotherapy and radiotherapy can impair fertility. Semen preservation by sperm banking (cryopreservation) should be offered to all patients.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/testicular-cancer/ CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210811_132749.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210318T190000 DTEND;TZID=Africa/Nairobi:20210318T203000 DTSTAMP:20260424T235428 CREATED:20210810T093714Z LAST-MODIFIED:20211024T153940Z UID:5829-1616094000-1616099400@kesho-kenya.org SUMMARY:Rectal Cancer – Multidisciplinary Approach DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Njoki Njiraini \nSponsor: Roche \nPresenters: \n\nDr. Anthony Ndiritu\, Consultant Clinical Oncologist\, Kenyatta National Hospital (KNH)\nDr. Alex Muturi\, Consultant General Surgeon & Endoscopist\, Kenyatta University Teaching Referral and Research Hospital (KUTRRH)\n\nManagement of colorectal cancer requires staging and risk assessment by a multidisciplinary team (MDT) to help in decision making and to audit and review the outcomes. Nutrition therapists are part of the MDT as the patients need to be nutritionally optimal before chemoradiotherapy and surgery for them to tolerate the effects of the treatment. Colorectal cancer is preventable and treatable if detected early. Early screening using immunochemical testing would help to pick the lesions when they are precancerous\, thus reducing cancer-related death by between 40-60%. A low index of suspicion of colorectal cancer among the caregivers is a major hindrance to timely diagnosis. For example\, patients with bloody stool may be treated for hemorrhage or other infections\, due to low suspicion of colorectal cancer. An accurate diagnosis would require a colonoscopy. Traditional\, extensive lymph node dissection with limited use of neoadjuvant radio is falling out of favor\, due to high functional genitourinary impairments and the need for experienced individuals to perform adequate dissection for outcomes. There is evidence that the dissection has similar recurrent rates as with neoadjuvant. Surgical site infections are a major challenge to surgery and require management. The cost of screening in Kenya is Ksh. 1000-2500. Management of colorectal cancer is by chemoradiation followed by surgery. The decision to take short-course radiotherapy (within a week) as opposed to the long course (5 to 6 weeks) should be guided by MDT. Patients with complete clinical response to chemoradiotherapy but who refuse to take surgery are at higher risk of local failure.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/rectal-cancer-multidisciplinary-approach/ CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210811_132818.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210311T190000 DTEND;TZID=Africa/Nairobi:20210311T203000 DTSTAMP:20260424T235428 CREATED:20210810T092706Z LAST-MODIFIED:20211024T153947Z UID:5826-1615489200-1615494600@kesho-kenya.org SUMMARY:Renal Cell Carcinoma DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Caroline Tonio\, Consultant Physician\, and Medical Oncologist\, Muranga County Hospital\, Kenya. Sponsor: Roche Presenters: \n\nDr. David K. Kimani\, Consultant Surgeon\, and Urologist\, Kenyatta National Hospital\nDr. Manel Haj Mansour\, Consultant Physician\, and Medical Oncologist\, Aga Khan University Hospital\n\nKidney cancers account for 5% and 3% of all adult malignancies in men and women. It’s the 7th most common cancer in men and the 10th most common cancer in women. Renal cell carcinomas (RCC) account for 80% of kidney cancers with a median age of 64 years. The risk factors include lifestyle\, comorbidities\, environmental exposures\, and genetic factors. Protective factors include the use of alcohol and coffee. Renal masses are primary or secondary\, the majority of which are RCC while a few are transitional cell carcinomas.  RCC is mainly asymptomatic\, but the advanced disease has a range of symptoms. Mortality rates from RCC have remained stable or have decreased slightly in developed countries\, mainly due to timely screening and early diagnosis. The current imaging modalities cannot reliably distinguish benign and malignant tumors or between indolent and aggressive tumor biology.  Consequently\, renal mass biopsy (RMB) should be considered when a mass is suspected to be hematologic\, metastatic\, inflammatory\, or infectious\, as they have a high sensitivity\, specificity\, and positive predictive value. The non-diagnostic rate of RMB can be reduced by a repeat biopsy. There is no specific molecular marker recommended for clinical prognostic use. Management of small renal masses is by active surveillance\, nephron-sparing surgeries\, ablative and radical therapies. Partial nephrectomy prioritizes the preservation of renal functions through optimum salvage of nephrons. Priority should be to maintain negative surgical margins and to avoid the possibility of positive surgical margins with a probability of local recurrence.  For complex tumors where partial nephrectomy is challenging\, radical nephrectomy is recommended. This involves the removal of the entire kidney with or without the adrenal gland and the lymph nodes. To remove the adrenal gland or not depends on findings of metastasis or direct invasion of the adrenal gland. The involvement of the adrenal gland is associated with a poor prognosis. In patients undergoing surgical excision of a renal mass\, a minimally invasive approach should be considered when it would not compromise oncologic\, functional\, and perioperative outcomes. Since RCC is radioresistant\, radiotherapy can only be used for palliative treatment. Systemic therapy should be prioritized over cytoreductive nephrectomy for patients with metastatic RCC.  First-line treatment is different for the good or intermediate and the poor-risk groups. Currently\, there is a paradigm shift to the use of immunotherapy treatment and immune checkpoint inhibitors. However\, the high cost of drugs and the fact that the National Hospital Insurance Fund (NHIF) may not cover the entire costs\, complicates effective treatment.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/renal-cell-carcinoma/ CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/08/885d0987-01df-49cb-99df-b91ddfefd49d.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210223T190000 DTEND;TZID=Africa/Nairobi:20210223T203000 DTSTAMP:20260424T235428 CREATED:20210810T094424Z LAST-MODIFIED:20211024T153955Z UID:5831-1614106800-1614112200@kesho-kenya.org SUMMARY:Management of Advanced Prostate Cancer DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Ahmed Komen \nSponsor: Beacon \nPresenters: \n\nProf. Asim Jamal Shaikh\, Associate professor of Medicine\, Consultant Medical Oncologist\, Aga Khan Hospital\, Nairobi\n\nProstate cancer is the most common cancer in Kenyan men\, where 80% of patients present with advanced disease\, encompassing a broad spectrum of diseases. The disease can be metastatic or non-metastatic. Metastatic hormone-sensitive prostate cancer is diagnosed by serum total PSA\, a biopsy\, conventional imaging (not readily available in Kenya)\, and Next-Generation Imaging (NGI).  NGI is useful in grouping the patients as high/low risk/volume\, depending on the disease burden. The Kenya national cancer screening guidelines guide the screening process\, which should be individualized with consultations between the physician and the patient. Management of Metastatic hormone-sensitive prostate cancer is by androgen deprivation therapy (ADT)\, achieved through surgical or medical castration. ADT should be started within 3 months of diagnosis. Advanced prostate cancer in patients who are hormone-sensitive or with high risk/volume requires a combination of ADT and chemotherapy treatment for a better outcome\, where disease volume or aggressiveness may help tailor treatment selection.  The addition of surgery and /or radiotherapy to systemic treatment may have a role in the treatment of newly diagnosed metastatic disease. Radiation therapy has a significant role in palliative treatment settings. Management of other histological subtypes of prostate cancer requires a histology review since the different subtypes are treated differently. Some patients transform from adenocarcinoma to neuroendocrine subtype hence may require ADT. However\, the degree of differentiation should be put into consideration. Prognosis is relatively poor\, hence it’s important to perform a pathology review in case the patient is not responding well to treatment. Prostate treatment affects a patient’s sexuality\, but ADT and vacuum-assisted devices help to restore sexual function. Considering the high cost of treatment\, chemotherapy and the use of generic forms of the drugs may be quite affordable.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/management-of-advanced-prostate-cancer/ CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210811_134639.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20210218T190000 DTEND;TZID=Africa/Nairobi:20210218T203000 DTSTAMP:20260424T235428 CREATED:20210810T100615Z LAST-MODIFIED:20211024T154003Z UID:5837-1613674800-1613680200@kesho-kenya.org SUMMARY:Molecular Testing For Breast Cancer and Implications For Treatment DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Peter Oyiro\, Medical Oncologist Kenyatta National Hospital Teaching and Referral Hospital \nSponsor: Beacon \nPresenters: \n\nDr. Sitna Mwanzi\, Consultant Physician and Medical Oncologist\, Aga Khan Hospital\, Nairobi\n\nBreast cancer is the most common type of cancer with 6799 new cases and 3107 death in Kenya in 2020. The mean age is 45-51 years. Molecular signature by microarray and immunohistochemistry has classified four molecular subtypes of breast cancer as including luminal A\, luminal B\, HER2+\, triple-negative breast cancer (TNBC)\, where luminal A and B are the most common molecular signatures  The molecular profiles are important prognostic and predictive factors in breast cancer. Luminal A has a better prognosis followed by luminal B\, hence patients with these subtypes are likely to be treated with surgery with or without adjuvant radiation therapy. HER2+ has a worse prognosis followed by TNBC\, hence patients with these subtypes will require chemotherapy and neoadjuvant. Genetic testing can be recommended in a case where a family member has a known pathogenic variant\, or in case of a personal history of breast cancer under the age of 45 years or within 45-60 years.  Additionally\, genetic testing is recommended in a new diagnosis of metastatic breast cancer\, and for young patients TNBC. Management for patients with BRCA pathogenic variant involves continued screening using mammography with tomosynthesis (digital mammography) and discussion on the risk reduction mastectomy and salpingo-oophorectomy. Relatives of such patients should be counseled on screening for pathogenic variants and if possible\, they should receive breast cancer screening at the age of 24-29 years\, and the screening should be done annually. The major challenges of genetic testing in Kenya include a lack of technical expertise and a shortage of genetic counselors\, to address the ethical concerns surrounding genetic counseling.  The tests are unavailable in many health care facilities. Furthermore\, the tests are not affordable\, since the samples have to be shipped to the USA for analysis. Traditionally\, the choice of adjuvant therapy was dependent on tumor size\, nodal status\, receptor status\, tumor grade\, age of the patient (younger patients were more likely to receive adjuvant chemotherapy). However\, more recent understanding has revealed that not all node-negative hormone receptor-positive patients benefit from chemotherapy.  Newer gene expression assays are helpful in tailoring treatment to avoid over and under-treatment.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/molecular-testing-for-breast-cancer-and-implications-for-treatment/ CATEGORIES:CME 2021,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210811_132829.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20201209T190000 DTEND;TZID=Africa/Nairobi:20201209T210000 DTSTAMP:20260424T235428 CREATED:20210817T112547Z LAST-MODIFIED:20211024T154010Z UID:5922-1607540400-1607547600@kesho-kenya.org SUMMARY:Shifting Paradigms In Triple-Negative Breast Cancer (TNBC) With Cancer Immunotherapy DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr.Njoki Njiraini Sponsor: Roche Presenters: \n\nProf. Asim Jamal Shaikh\, Associate professor of Medicine\, Consultant Medical Oncologist\, Aga Khan Hospital\, Nairobi.\nProf. Peter Schmid\, Lead\, Centre for Experimental Cancer Medicine\, Barts Cancer Institute\, St Bartholomew’s Hospital the Queen Mary University of London.\nProf. Nadia Harbeck\, MD LMU Breast Center.\n\nTriple-negative breast cancer (TNBC) is a heterogeneous disease with differential gene expression profiles. The morphological subtypes of TNBC include ER\, PR\, and Her 2 Neu Negative cancers. Hormone receptor-negative patients are usually young (mean age 48.8-34%) and are diagnosed with grade III tumors. The biomarkers are different for African\, African American\, and caucasian women The differences have clinical and biological implications which could be targeted for the development of personalized therapeutics. Testing for immunohistochemistry and participation in clinical trials may improve disease management\, which is a global challenge as well as in Kenya. Poor handling of collected samples\, challenges with sample analysis\, quality control\, and data registry affect data collection in Kenya. There are challenges with the correct pathologic diagnosis\, as a result of differences in diagnostic methods. Testing for immunohistochemistry and participation in clinical trials may improve disease management. Data generated by molecular and genomic profiling is promising to open new therapeutic options. Today\, neoadjuvant therapy is the standard for early TNBC management. Immunotherapies targeting single-agent anti-PD-L1/PD-1 in combination with chemotherapy are effectively treating TNBC\, with good tolerability. Sacituzumab is a new antibody-conjugate in the treatment of TNBC. Other treatment options involve offering multiple lines of treatment\, where standard chemotherapy contains anthracyclines and taxanes. However\, the cost of treatment and diagnostics is still a big challenge in Kenya.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/shifting-paradigms-in-triple-negative-breast-cancer-tnbc-with-cancer-immunotherapy/ CATEGORIES:CME 2020,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/08/8a91fcc1-a426-4a41-b89c-f636ecccd1f4.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20201121T080000 DTEND;TZID=Africa/Nairobi:20201121T170000 DTSTAMP:20260424T235428 CREATED:20210420T145304Z LAST-MODIFIED:20230711T094207Z UID:4709-1605945600-1605978000@kesho-kenya.org SUMMARY:The 6th Kenya International Cancer Conference DESCRIPTION:[vc_row][vc_column] \n \n Theme: Making Strides Towards Quality Cancer Care \n \n \n [vc_tta_accordion][vc_tta_section title=”Executive Summary” tab_id=”1618600243140-acca4fba-be67dc3f-f6dd”][vc_column_text] \nEXECUTIVE SUMMARYThere is need for patient-centered\, high-quality\, and value-based care in the management of cancers in general. This includes the whole continuum from prevention\, timely access to screening\, diagnosis\, treatment and palliative care services; and improving rehabilitation and support activities. \nPracticing Oncologists are invariably asking questions around value-based care in oncology. For the first time\, KESHO held a virtual forum looking critically at the value of cancer care in Kenya and Africa. The 2020 Kenya International Cancer Conference looked at Value as a measure of a patients’ expectations of care and how this can be translated into cost effectiveness\, and how these two factors can be combined in a low-resource setting. \nThe conference had an impressive line-up of presenters from across the globe sharing their experiences on how HCPs can continue to deliver quality care as well as the considerations for providing the quality of care in the Covid environment. The virtual event incorporated several breakout sessions including site-specific discussions around delivering care as well as the related challenges\, actual management of cancer patients\, policy and advocacy\, palliative care\, nursing care in oncology\, haematological conditions Click here to view agenda \nThe event also highlighted some of the challenges around delivering care and how to restructure and build systems that deliver effective care. Also\, part of the Agenda was a collaborative session with AORTIC where presenters shared anecdotal experiences around research\, education\, training and building regional networks. \nThere is an increasing consciousness around how we as a continental community can generate our own evidence and look at what our best practice is\, and a critical component to this is setting up our own clinical trials in Africa. Some of these issues were discussed by the conference keynote speakers who gave their experiences on clinical trials in Africa and offered practical tips that HCPs can use to build up our continental collaborations and gather robust clinical data for improved patient outcomes. \nThe conference also included a session looking at media and the oncologist which touched on effective communication with patients\, effective communication with media and how to effectively package key messages for maximum impact. \nThe 2020 Kenya International Cancer (Virtual) Conference attracted over 400 attendees from various countries around the world including Kenya\, Nigeria\, Ghana\, Rwanda\, Ethiopia\, Egypt\, UK\, USA\, China\, SA\, Netherlands\, Sudan\, India\, Tanzania\, Libya\, Zimbabwe\, Germany\, Argentina\, Switzerland and many others. The 2020 KICC programme featured talks from leading specialists as well as primary care professionals from across Africa and the world. \n[/vc_column_text][/vc_tta_section][vc_tta_section title=”Abstracts” tab_id=”1618600243182-22e4f313-bf2fdc3f-f6dd”][vc_row_inner][vc_column_inner width=”1/3″][vc_column_text]\n\n\n PDF Loading...\n \n \n \n \n\n[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/3″][vc_column_text]\n\n\n PDF Loading...\n \n \n \n \n\n[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/3″][vc_column_text]\n\n\n PDF Loading...\n \n \n \n \n\n[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_tta_section][vc_tta_section title=”Sponsors” tab_id=”1618600981491-a82fabd7-47e6dc3f-f6dd”][vc_column_text] \nThe 6th Kenya International Cancer Conference attracted 13 exhibitors including sponsors. \n[/vc_column_text][vc_row_inner][vc_column_inner][vc_images_carousel images=”6636\,4558\,4559\,4560\,4561\,4648\,4645\,4698\,6874\,6876\,6878\,6879\,6881″ img_size=”full” onclick=”link_no” slides_per_view=”5″ wrap=”yes”][/vc_column_inner][/vc_row_inner][/vc_tta_section][vc_tta_section title=”Attendance” tab_id=”1618603042055-86340cec-1051dc3f-f6dd”][vc_column_text] \nThe 2020 Kenya International Cancer (Virtual) Conference attracted over 400 attendees. These included haematologists\, oncologists\, pathologists\, nurses\, radiotherapists\, surgeons\, patient advocates and medical students. The Conference brought together top multi-disciplinary professionals from across Africa and the globe. They shared how they were making strides towards quality cancer care especially under the shadow of the pandemic. \n[/vc_column_text][vc_row_inner][vc_column_inner][vc_single_image image=”7092″ img_size=”full” alignment=”center”][/vc_column_inner][/vc_row_inner][/vc_tta_section][vc_tta_section title=”Program” tab_id=”1618940648899-abece2ab-d320″][vc_column_text] \nFind below the programme for the 6th Kenya International Cancer Conference. \n\n\n\n PDF Loading...\n \n \n \n \n\n\n[/vc_column_text][/vc_tta_section][vc_tta_section title=”Resources” tab_id=”1618603068054-1a862002-c186dc3f-f6dd”][vc_row_inner][vc_column_inner][vc_column_text] \n\n\n\n PDF Loading...\n \n \n \n \n\n\n[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_tta_section][vc_tta_section title=”Photos” tab_id=”1618603088222-d75bc43c-cc85dc3f-f6dd”][vc_row_inner][vc_column_inner][vc_column_text]The photos will be posted soon.[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_tta_section][/vc_tta_accordion][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n \n \n \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/the-6th-kenya-international-cancer-conference/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:Conferences END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20201029T190000 DTEND;TZID=Africa/Nairobi:20201029T203000 DTSTAMP:20260424T235428 CREATED:20210817T103556Z LAST-MODIFIED:20211024T154027Z UID:5909-1603998000-1604003400@kesho-kenya.org SUMMARY:Management Of Sickle Cell Disease: A Multidisciplinary Approach DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Gladwell Gatheca Sponsor: Novartis Presenters: \n\nDr. Fredrick Okinyi\, Lecturer\, hematologist\, University of Nairobi\, Kenya\nDr. Esther Nafula\, Palliative Care Specialist and Head of Department\, KNH Palliative Care Unit\n\nSickle cell disease (SCD) is a neglected genetic disease in sub-Saharan Africa that is responsible for 5-16% of mortality in children under 5 years. Approximately 75% of children die before 5 years of age. SCD has a mortality rate of 58/1000 cases per year. The goals of clinical assessment in to give an impression and confirm the diagnosis in new patients\, to determine the symptomatology\, acute or chronic complications\, stable or unstable in known cases\, to classify the type of crisis and precipitating factors in acutely sick patients\, to decide on the level of care as outpatient/inpatient or referral. Diagnosis for new patients is based on clinical presentation\, family history\, clinical features (signs and symptoms)\, and laboratory testing which can be considered as neonatal screening. Preliminary laboratory tests include full blood counts\, reticulocyte counts\, blood film morphology. Sickling tests can be easily performed in the laboratory of lower-level facilities. Since the test is positive for individuals with sickle cell disease as well as in sickle cell trait\, a Hb separation technique is necessary for a positive test. Confirmatory tests include hemoglobin electrophoresis (HE)\, High-performance Liquid Chromatography (HPLC)\, and Isoelectric Focusing (IEF). The point of care rapid tests has high specificity and sensitivity when compared with the HPLC. They are useful in lower-level facilities. Although rapid tests can identify the hemoglobins Hb A\, Hb S\, and Hb C\, they cannot quantify the different hemoglobins or accurately identify some of the other forms of SCD such as Hb S beta-thalassemia. SCD patients should attend clinics as an outpatient management practice. Acute complications should be managed. Fluid management is an important aspect since SCD patients are at risk of dehydration due to impaired renal concentrating power and poor fluid intake. Simple transfusion may use packed red blood cells\, where the donor hematocrit should be about 0.6. Exchange transfusion may be undertaken to rapidly reduce the percentage of sickle cells in circulation\, especially in severe sickle chest syndrome. The complications of the sickle cell disease range from mild to severe and vary among individuals. Counseling is very important in pre-marital\, early childhood\, Adolescence/ adulthood\, and end of life. Pain management involves the use of strong opioids for severe pain\, weak opioids for moderate pain\, and regular paracetamols.  SCD is incurable often leading to premature death. The patients should be helped to achieve a good death\, mainly through control of pain and other physical symptoms\, accepting death is inevitable\, forgiving others\, reconciling with self\, family\, and God\, and being in control of the dying process.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/management-of-sickle-cell-disease-a-multidisciplinary-approach/ CATEGORIES:CME 2020,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_163728.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20201027T190000 DTEND;TZID=Africa/Nairobi:20201027T203000 DTSTAMP:20260424T235428 CREATED:20210813T140618Z LAST-MODIFIED:20211024T153721Z UID:5894-1603825200-1603830600@kesho-kenya.org SUMMARY:Breast Cancer Management: A Comprehensive Approach Part 3 DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Sponsor: AstraZeneca Presenters: \n\nDr. Daniel Ojuka\, Consultant General & Breast Surgeon & Lecturer\, University of Nairobi\nDr. Andrew Odhiambo\, Consultant Medical Oncologist & Lecturer\, University of Nairobi\n\nBreast cancer is the most common cancer in women globally. Although the surgery was previously the most successful form of treatment; it was associated with mortality (approximately 15%) and increased morbidity\, hence was abandoned in the 1960s. Consequently\, advances in general anesthesia and antiseptic techniques facilitated more extensive procedures. In Kenya\, the current changes in breast cancer management are driven by early detection and diagnosis and timely referrals\, resulting in better outcomes. Unfortunately\, late diagnosis is still frequent.  The current breast cancer management approach is multidisciplinary\, consisting of a multidisciplinary team (MDT)\, of highly qualified specialists and a coordinator. The MDTs are economical and result in service improvement and better outcomes. To date\, breast surgery involves MRM-Auchoncloss\, skin\, and nipple-sparing mastectomy techniques\, which are selected depending on patient morphology\, breast ptosis\, and type of reconstruction planned.  Since the female breast is a symbol of beauty\, fertility\, and femininity\, and surgery causes disfigurement\, mastectomy for younger women requires proper communication and engagement with the patient\, especially on the use of an aesthetic approach to breast conservation and rehabilitation therapy. Alternative approaches to surgery include hormonal therapy\, targeted therapy\, and chemotherapy\, where the choice depends on the stage\, setting\, disease biology\, patient characteristics\, and the genomic patterns of the patients. A combination of approaches such as the use of neoadjuvant chemotherapy before surgery has proven to be beneficial especially in ulcerated patients. Considering the anatomical and molecular staging\, the stage-based treatment survival rate is dependent on the subtypes of breast cancer. The national cancer treatment protocols and training programs for capacity building have been availed to all the counties by the Ministry of Health\, Kenya\, to support the treatment of cancer patients\, especially in the counties.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/breast-cancer-management-a-comprehensive-approach/ CATEGORIES:CME 2020,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_163708.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20201021T190000 DTEND;TZID=Africa/Nairobi:20201021T203000 DTSTAMP:20260424T235428 CREATED:20210813T135003Z LAST-MODIFIED:20211024T154040Z UID:5888-1603306800-1603312200@kesho-kenya.org SUMMARY:Breast Cancer Early Diagnosis and Screening Part 2 DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Vera Manduku Presenters: \n\nDr. Mary Nyangasi\, Head of Division\, National Cancer Control Program\, Ministry of Health\, Kenya\nDr. Miriam Mutebi\, Consultant\, Breast Surgical Oncologist\, Aga Khan University Hospital\n\nThe ministry of health is commemorating the annual national breast cancer awareness month 2020 by giving hope and saving the lives of breast cancer patients. Globally\, cancer is a major cause of death\, accounting for 1 out of 6 deaths annually. Over 70% of deaths occur in low and middle-income countries\, where breast cancer accounts for 6.6% of all cancer deaths. In Kenya\, cancer is the second leading cause of death from non-communicable diseases\, accounting for 7% of overall mortality. Breast cancer is the third leading cause of death after esophageal and cervical cancers. Good prognosis is associated with timely screening and early detection\, followed by timely treatment. Unfortunately\, awareness and uptake of screening services remain low in Kenya. Consequently\, 70% of breast cancer cases are diagnosed in advanced stages. Since survival of breast cancer patients is highly dependent on the stage of diagnosis\, a low survival rate is observed in stage IV patients. To support the management of breast cancer\, the ministry of health\, Kenya has put infrastructure for screening mammography in all the 47 County Referral Hospitals. In addition\, the ministry has provided national cancer screening guidelines (2018) to guide an organized and unified approach for screening priority cancers including cervix\, breast\, colorectal\, prostate\, and retinoblastoma.  Mammography is the recommended method of screening for women in the average-risk population\, and the only screening modality shown to reduce breast cancer mortality. Previous studies have shown that screening mammography helps with the early detection of cancer and greatly reduces breast cancer deaths for women aged 40-74 years as well as those above 74 years. However\, mammography is very costly and is only recommended for countries with good health infrastructure that can afford long-term programs. Other early detection techniques include a clinical breast examination\, ultrasound\, monthly breast self-examination\, and breast self-awareness. Breast cancer management in low and middle-income countries is complicated by poor health systems\, poverty\, and retrogressive cultural practices. In these countries\, awareness of early signs and symptoms and screening by clinical breast examinations are recommended for the early detection of breast cancer. In Kenya\, screening is mainly opportunistic\, mainly due to challenges associated with lack of equipment\, radiologists\, and radiology personnel. The risk of breast cancer is stratified into two: the average-risk population\, accounting for 80%\, while the high-risk population (20%). While there is a need for risk reduction strategies\, the risks involved in mammography are non-lethal; hence screening benefits outweigh the risks involved. Some of the risks include recall for additional imaging\, needle biopsy\, false positives\, anxiety\, and over-diagnosis. Lifestyle and environmental factors can have an impact on breast cancer risk. Some of the risk reduction measures include maintaining a healthy weight\, exercising regularly\, and limiting the amount of alcohol.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/breast-cancer-early-diagnosis-and-screening/ CATEGORIES:CME 2020,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_163658.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20201013T190000 DTEND;TZID=Africa/Nairobi:20201013T203000 DTSTAMP:20260424T235428 CREATED:20210813T134000Z LAST-MODIFIED:20211024T154048Z UID:5883-1602615600-1602621000@kesho-kenya.org SUMMARY:Childhood Cancers and Early Detection DESCRIPTION:[vc_row][vc_column][vc_column_text] \nModerator: Dr. Sitna Mwanzi \nPresenters: \n\nDr. Valerian Mwenda\, Medical epidemiologist\, Lead Cancer registration\, Monitoring\, Evaluation and Research\, Division of National Cancer Control Program\, Ministry of Health.\nDr. Doreen Karimi Mutua\, Paediatric\, hematologist/ oncologist\, Gertrude’s Children’s Hospital\, Childhood Cancer Initiative\n\nChildhood cancer is becoming a public health crisis in the developing world. In high-income countries\, the childhood cancer prevalence is only 20%\, with up to 80% cure rates. Low and middle-income countries account for 80% of all new cancer cases and less than 20% survival rates. In 2018\, 3000 new cases of childhood cancers were reported in Kenya\, where the survival rate is less than 19-30%. The low survival rate is attributed to the late presentation of patients\, lack of knowledge and awareness of symptoms and signs among health care workers\, weak referral systems\, few cancer diagnostic and treatment centers\, cultural beliefs and myths\, and financial constraints. To overcome these challenges\, there is a need to raise awareness among caregivers and health care workers on early warning signs\, encourage health-seeking behavior among Kenyans\, strengthen referral systems to avoid time wastage\, equip and train staff to diagnose and treat\, adopt evidence-based protocols for the treatment of cancer patients\, maintain data on the outcomes\, and use it for treatment and resource planning. The global initiative for childhood cancer target for 2030 is to realize a double cure rate\, ensuring at least 60% survival for children with cancer globally\, and reducing suffering for all. To achieve this\, efforts are being put in place to increase the capacity of countries to provide quality services for children with cancer\, and to increase the prioritization of childhood cancer at the global\, regional\, and national levels. According to Kenya National Cancer Registry\, the most common childhood cancers are Leukemia\, Retinoblastoma\, Renal\, Lymphoma\, and Central Nervous System. The risk factors are majorly unknown\, though exposure to ionizing radiation and infectious agents has been associated with some cancers. The goal of the Kenya Cancer Policy is to provide a multi-sectoral framework to comprehensively address the cancer burden in the country. The national cancer control strategy (2017-2022) aims to optimize treatment and palliative care for childhood cancers. The national cancer screening guidelines guide early diagnosis while the national cancer treatment protocols guide treatment.  Barriers to effective childhood cancer control include a low level of awareness\, low index of suspicion among the caregivers\, poor referral systems\, and inadequate access to palliative care. Other system challenges include poor access to health care\, lack of finances\, and inadequate surveillance and tracking systems.  To counter these challenges the ministry of health Kenya is increasing advocacy\, training among the health care providers\, and universal health coverage.  Early detection of childhood cancer is key to improved survivorship and health outcomes\, timely access to treatment and care\, lower intensity of treatment\, cost-saving for families and health systems\, and a lower burden of short and long-term toxicity. \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n  \n  \n  \n  \n\n\n  \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/childhood-cancers-and-early-detection/ CATEGORIES:CME 2020,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_163619.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20201008T191500 DTEND;TZID=Africa/Nairobi:20201008T203000 DTSTAMP:20260424T235428 CREATED:20210812T095227Z LAST-MODIFIED:20211024T153727Z UID:5878-1602184500-1602189000@kesho-kenya.org SUMMARY:The Role of Immunotherapy in Cancer Management DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Miriam Mutebi \nSponsor: Beacon \nPresenters: \n\nProf. Asim Jamal Shaikh\, Associate professor of Medicine\, Consultant Medical Oncologist\, Aga Khan Hospital\, Nairobi.\n\nImmunotherapy is a type of cancer treatment that boosts the body’s natural defenses to fight cancer cells. It uses substances made by the body or in a laboratory to improve how your immune system works to find and destroy cancer cells. Traditional therapies such as surgery\, radiation\, and cytotoxic/targeted therapy target tumor cells\, while immunotherapy harnesses the body’s immune system to fight diseases. Anti-tumor immunotherapy includes cancer vaccines that educate T cells to better recognize and kill the pre-existing tumor. Adoptive immunotherapy activates and increases T cell numbers to better kill tumor cells. Immunomodulation uses drugs or antibodies to either increase stimulation or to overcome immune inhibition. Many tumors escape the immune response by creating an immunosuppressive microenvironment that prevents an effective anti-tumor response\, mainly through the involvement of the immune checkpoints located in the central or peripheral regions. The immune checkpoints PD-L1 binds to PD-1 and inhibits T cell killing of tumor cell\, therefore\, blocking PD-L1 or PD-1 allows T cell killing of tumor cells\, while CTLA4 regulate the early phase of activation of naïve and memory T cells in response to T cell receptor (TCR) stimulation by peptides presented by MHC ligands expressed by antigen-presenting and processing cells. Its upregulation prevents normal T cell activation. Several checkpoint inhibitors with FDA approval are in clinical use and have proven to be highly effective in the treatment of relapsed\, progressive solid cancers\, with relatively mild but distinct safety profiles. Some immune checkpoint inhibitors available in Kenya\, are quite costly\, and hence National Hospital Insurance Fund (NHIF) is too little to cover for this treatment. Aga Khan is building capacity for PD-L1 analysis\, an immunohistochemistry test\, in addition to next-generation sequencing. More data is required on the safety of immunotherapy and its use on immunocompromised individuals e.g. HIV\, and those with autoimmune diseases\, Since several clinical trials\, are in progress; more new indications are likely to emerge.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/the-role-of-immunotherapy-in-cancer-management/ CATEGORIES:CME 2020,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210812_124901.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20200929T190000 DTEND;TZID=Africa/Nairobi:20200929T203000 DTSTAMP:20260424T235428 CREATED:20210604T163946Z LAST-MODIFIED:20211024T154727Z UID:5302-1601406000-1601411400@kesho-kenya.org SUMMARY:Management of Hormone Receptor Positive Breast Cancer DESCRIPTION:[vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/management-of-hormone-receptor-positive-breast-cancer/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2020,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/06/image_2021-06-04_193725.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20200915T191500 DTEND;TZID=Africa/Nairobi:20200915T203000 DTSTAMP:20260424T235428 CREATED:20210817T111009Z LAST-MODIFIED:20211024T154755Z UID:5918-1600197300-1600201800@kesho-kenya.org SUMMARY:Management of Neuroendocrine Tumors DESCRIPTION:[vc_row][vc_column][vc_column_text] \n\n\n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]Moderator: Dr. Sitna Mwanzi \nSponsor: Novartis \nPresenters: \n\nNjoki Njiraini\, a consultant clinical oncologist based at the Cancer Centre in Kenyatta University Teaching Research and Referral Hospital.\n\nNeuroendocrine Neoplasms arise from diffuse neuroendocrine cells in the body and are broadly divided into well-differentiated neuroendocrine tumors (NETs)\, including the sporadic small intestine\, pancreatic\, thorax\, and thymus NETs\, and poorly differentiated neuroendocrine carcinomas (NECs)\, classified based on differentiation\, Ki67 levels\, and mitotic figures. NETs arise from neuroendocrine cells throughout the body. There has been increasing incidence over the last 15 years\, with a male preponderance and a more adverse outcome. Diagnosis is mainly through histology and immunohistochemistry. Staging for NECs is mainly by adenocarcinoma staging system\, which mainly involves imaging through CT scan\, MRI\, Contrast-Enhanced USS\, endoscopic USS\, and functional imaging. Treatment is dependent on TNM staging and grading of the disease and includes surgery\, somatostatin analogs\, hepatic-directed therapies\, and chemotherapeutics. For a patient with carcinoid syndrome\, the short-acting octreotide can be considered first\, while waiting for long-acting octreotide to act. Locally\, therapies are available in 20 mg from Novartis retailing at 68000 Kenya shillings\, but 30mg are also available in the market through other distributors. The toxicity profiles should be put into consideration e.g. diarrhea\, although sometimes it’s difficult to differentiate drugs’ side effects from the initial tumor signs. Neuroendocrine carcinomas are classified as small or large cells and mostly the patients have poor outcomes. There is a need to improve imaging and multidisciplinary teams to share local experiences of neuroendocrine patients.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n\n\n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/management-of-neuroendocrine-tumors-2/ CATEGORIES:CME 2020,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_171140.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20200908T191500 DTEND;TZID=Africa/Nairobi:20200908T203000 DTSTAMP:20260424T235428 CREATED:20210817T105953Z LAST-MODIFIED:20211024T154816Z UID:5914-1599592500-1599597000@kesho-kenya.org SUMMARY:Management of Iron Overload DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Paresh Dave \nSponsor: Novartis \nPresenters: \n\nPeter Oyiro\, Medical Oncologist Kenyatta National Hospital Teaching and Referral Hospital\n\nIron overload is a poly etiologic condition characterized by a moderate to severe increase in the body iron that has or will have negative effects secondary to iron deposition in tissues or body organs. It may be hereditary or acquired. It is important to detect the disease before organ damage occurs. Iron overload affects overall survival partly due to the underlying biology of the disease but also because of the sequelae of iron overload\, including cardiomyopathy\, cardiac events\, liver disease\, and the development of diabetes. For patients with higher serum ferritin levels\, the 100-day post-transplant mortality is worse with inferior overall survival (OS) and a higher rate of graft vs host disease.  Therefore\, iron chelation therapy can improve OS and is effective at reducing serum ferritin levels\, cardiac events\, and diabetes in patients with blood-transfusion-related iron overload. Compliance is highly encouraged to realize successful treatment. The safety profile of each chelator should be evaluated before the initiation of treatment. Patients receiving chemotherapy and who have a drop in blood count parameters require evaluation to find out the causes. Iron studies are required to generate more data. Iron supplementary can be toxic. Patients with severe organ dysfunction can have a combination of iron chelation therapy.  Ferritin levels should be done every 3 months.  Iron chelation OS is not contraindicated in HIV patients with evidence of iron overload.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/management-of-iron-overload/ CATEGORIES:CME 2020,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_170945.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20200827T070000 DTEND;TZID=Africa/Nairobi:20200827T203000 DTSTAMP:20260424T235428 CREATED:20210604T162505Z LAST-MODIFIED:20211024T154948Z UID:5294-1598511600-1598560200@kesho-kenya.org SUMMARY:Cancer and Thrombosis Current Perspective DESCRIPTION:[vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/cancer-and-thrombosis-current-perspective/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2020,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/06/image_2021-06-04_193129.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20200811T191500 DTEND;TZID=Africa/Nairobi:20200811T201500 DTSTAMP:20260424T235428 CREATED:20210813T143324Z LAST-MODIFIED:20250622T142511Z UID:5898-1597173300-1597176900@kesho-kenya.org SUMMARY:Emerging Therapies in Hodgkin's Lymphoma Management - Treatment Beyond The Basics DESCRIPTION:[vc_row][vc_column][vc_column_text] \nModerator: Dr. Miriam Mutebi \nSponsor: Takeda\, a pharmaceutical company with a patient assistance program for Hodgkin’s lymphoma in Kenya. \nPresenters: \n\nDr. Anna Sureda\, Head of the Clinical Hematology Department and the Stem Cell Transplantation program of Institut Catala d’Oncologia – Hospitalet\, Barcelona\n\nHodgkin’s lymphoma (HL) is one of the most curable hematological malignancies with first-line treatment\, which is a combination of radiotherapy and chemotherapy. Autologous hematopoietic stem cell transplantation (auto-HCT) is the standard therapy for HL patients relapsing after first-line chemotherapy. The use of allogeneic stem cell transplantation (ASCT) has improved the overall survival (OS) of patients over time.  To improve the landscape of chemotherapy treatment for refractory disease\, a new drug\, Brentuximab vedotin\, has been introduced. This drug is an antibody-drug conjugate (ADC) consisting of 3 components; it binds to CD30 forming a complex that is internalized and traffics to the lysosome. The drug was granted accelerated approval by the US FDA in 2011.  The European Medicines Agency (EMA) approved this drug in 2012 for the treatment of adult patients with relapsed or refractory CD30+ HL\, anaplastic large cell lymphoma\, and those at increased risk of relapse or progression following ASCT. The efficacy reported as median observation time from the first dose at study closure was 35.1 months (1.8-72.9). Studies revealed that Brentuximab vedotin and ESHAP are highly effective as second-line therapy for Hodgkin’s patients. Brentuximab vedotin was the first targeted therapy that was tested in patients with relapsed/refractory HL. It was very effective as a single drug in patients that relapse or progress after auto-HCT. Brentuximab vedotin is able to potentially increase the number of patients that are candidates to auto-HCT. It improves progression-free survival (PFS) in those patients with a high risk of relapse after auto-HCT when used as a consolidation strategy. It has demonstrated an adequate and safe toxicity profile\, even in HIV-positive patients with HL. Brentuximab vedotin is being used in other settings with very interesting results (RR setting in combination with chemotherapy\, first line). However\, the cost of the treatment in Kenya is quite high; a single vial costs Kshs. 330\,000. A patient assistance program in partnership with Takeda is helping patients in Kenya who cannot afford to pay\, to complete their treatment. Although this program is run in private hospitals\, physicians seeing patients at public facilities can refer the patients to the private facilities for assistance\, but continue to follow up on the patients. \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/emerging-therapies-in-hodgkins-lymphoma-management-treatment-beyond-the-basics/ CATEGORIES:CME 2020,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_170809.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20200730T191500 DTEND;TZID=Africa/Nairobi:20200730T203000 DTSTAMP:20260424T235428 CREATED:20210810T101728Z LAST-MODIFIED:20250622T142511Z UID:5839-1596136500-1596141000@kesho-kenya.org SUMMARY:Ovarian Cancer\, The Good\, The Bad\, And The Ugly DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Andrew Odhiambo\, Consultant Medical Oncologist & Lecturer\, University of Nairobi \nSponsor: Merck \nPresenters: \n\nDr. Benjamin Odongo Elly\, Gynecologic Oncologist at Moi Teaching and Referral University.\n\nMoi Teaching and Referral Hospital (MTRH) cancer center offers a holistic approach to cancer treatment. Germ cell tumors account for 10-115% of all ovarian tumors and affect young females of reproductive age. They are very chemosensitive hence are curable\, using fertility-sparing surgery. Stromal tumors account for 3-5% of all ovarian tumors and affect women of all ages. These tumors are diagnosed early and are histologically low-grade\, with a good prognosis\, when treated with surgery\,  followed by adjuvant treatment. However\, some tumors are aggressive and lethal. Epithelial tumors represent 80-85% of all ovarian tumors. They have a poor prognosis and are always detected late. Warning signs include abdominal bloating\, abdominal/pelvic pain\, bowel/bladder symptoms\, and irregular vaginal bleeding. Prevention of ovarian cancer is by avoidance of risk factors and prophylactic surgery in high-risk women. There is currently no good screening test for the general population. Diagnosis is by appropriate physical examination\, pelvic/transvaginal ultrasound\, tumor markers\, and CT scan. The majority of patients are diagnosed with advanced-stage disease (stage III or IV) leading to poor overall 5-year survival. However\, patients are living longer with the disease due to advances in surgery and chemotherapy treatment. As a country\, there is a need to improve the early diagnosis of ovarian cancer through advocacy\, patient education\, human resource\, training capacity building\, and availing resources to the health care facilities.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/ovarian-cancer-the-good-the-bad-and-the-ugly/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2020,Webinar Recording Available END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20191121T200000 DTEND;TZID=Africa/Nairobi:20191121T220000 DTSTAMP:20260424T235428 CREATED:20210420T152935Z LAST-MODIFIED:20250622T142511Z UID:4731-1574366400-1574373600@kesho-kenya.org SUMMARY:TOPIC: Management of Brain Tumors DESCRIPTION:[vc_row][vc_column][vc_column_text] \nFinally\, KESHO partnered with the Neurological Society of Kenya to discuss the management of brain tumors with a stimulating surgical perspective from Dr Edwin Mogere Neurosurgeon and an in-depth discussion of management of medical symptoms from brain tumors by Dr Judy Kwasa Neurologist. \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-management-of-brain-tumors/ LOCATION:Crowne Plaza Hotel CATEGORIES:CME 2019,Webinar Recording Available END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190829T200000 DTEND;TZID=Africa/Nairobi:20190829T220000 DTSTAMP:20260424T235428 CREATED:20210420T153545Z LAST-MODIFIED:20250622T142511Z UID:4736-1567108800-1567116000@kesho-kenya.org SUMMARY:TOPIC: BCR-ABL and OSTEOGENIC SARCOMA DESCRIPTION:[vc_row][vc_column][vc_column_text]We took a well-deserved break in July 2019 and came back in August for a mixed presentation on CML and osteogenic sarcoma from Prof Nicholas Abinya Medical Oncologist and Dr Mohammed Ezzi Medical Oncologist. The outcome for patients with CML has significantly improved with TKI therapies\, yet challenges persist in adequate monitoring which is expensive. The lack of co-ordinated multidisciplinary care needed for osteogenic sarcoma led to many lost to follow up and incomplete treatments with poor outcomes. MDTs prior to treatment is a potential strategy for reversing this trend.[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-bcr-abl-and-osteogenic-sarcoma/ LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya CATEGORIES:CME 2019,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190829T170000 DTEND;TZID=Africa/Nairobi:20190829T200000 DTSTAMP:20260424T235428 CREATED:20210420T153328Z LAST-MODIFIED:20250622T142510Z UID:4734-1567098000-1567108800@kesho-kenya.org SUMMARY:SSA Breast Cancer DESCRIPTION:[vc_row][vc_column][vc_column_text]Another busy month for us with three meetings in October. First off\, Prof Asim Jamal Medical Oncologist gave an excellent overview of presentation\, diagnosis and management of neuroendocrine tumors which are not as rare as originally felt. KESHO then partnered with Pathologists Lancet Kenya to discuss molecular diagnostics in hemato-oncology. Speakers from France and our very own experts deliberated on the changing landscape of hemato-oncology and what is practical in our setting. Finally\, a multidisciplinary webinar session on breast cancer concluded our sessions for the month in recognition of the Breast Cancer Awareness month\, with presentations from Dr. Gladwell Kiarie Medical Oncologist\, Dr. Fred Okuku Medical Oncologist\, Dr. Aba Anoa Scott Radiation/Clinical Oncologist and Prof. Ronald Wasike Breast Surgeon.[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/ssa-breast-cancer/ LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya CATEGORIES:CME 2019 END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190627T110000 DTEND;TZID=Africa/Nairobi:20190627T200000 DTSTAMP:20260424T235428 CREATED:20210420T154157Z LAST-MODIFIED:20250622T142511Z UID:4738-1561633200-1561665600@kesho-kenya.org SUMMARY:TOPIC: Paediatric Malignancies; Optimising Care In Acute Leukaemia DESCRIPTION:[vc_row][vc_column][vc_column_text]We directed our focus on hematology and this time we concentrated on pediatric malignancies. Dr. Jamila Rajab Consultant Haematologist\, Dr. Grace Mbatia Paediatric Oncologist and Dr Festus Njuguna Paediatric Oncologist. We got a glimpse on the myriad challenges our colleagues in hematology face in the management of pediatric hematological malignancies including complicated regimens\, high rate of drop outs and poor supportive care. The outcome was to continue in the process of development of national treatment protocols that can be used which can also help in comparing treatment outcomes in the different settings.[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-paediatric-malignancies-optimising-care-in-acute-leukaemia/ LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya CATEGORIES:CME 2019,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190523T200000 DTEND;TZID=Africa/Nairobi:20190523T220000 DTSTAMP:20260424T235428 CREATED:20210420T154450Z LAST-MODIFIED:20250622T142511Z UID:4740-1558641600-1558648800@kesho-kenya.org SUMMARY:TOPIC: Colon Cancer; A Multidisciplinary Approach DESCRIPTION:[vc_row][vc_column][vc_column_text]This was a busy month for our members with three educational events! Dr. Joe Ruturi Cardiothoracic Surgeon and Dr. Solomon Mutua Clinical Oncologist started off the month with discussions on upper GI cancers\, in particular esophageal cancer. KESHO collaborated with ROCHE in their sub-Saharan MPANGO two-day meeting in which many of our members were speakers. The conference focused on triple negative and HER2 breast cancer\, colon and lung cancer. The month ended with an excellent multidisciplinary meeting on colon cancer spearheaded by our very own past Chair\, Dr. Gladwell Kiarie Medical Oncologist and Dr. Rajendra Chauhan Surgical Oncologist. There was a lot of input from our surgical and radiation colleagues.[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-colon-cancer-a-multidisciplinary-approach/ LOCATION:Radisson Blu\, Upperhill Nairobi\, Nairobi\, Nairobi\, 00100\, Kenya CATEGORIES:CME 2019,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190427T200000 DTEND;TZID=Africa/Nairobi:20190427T220000 DTSTAMP:20260424T235428 CREATED:20210420T155152Z LAST-MODIFIED:20250622T142511Z UID:4743-1556395200-1556402400@kesho-kenya.org SUMMARY:TOPIC: HIV Malignancies Symposium DESCRIPTION:[vc_row][vc_column][vc_column_text]KESHO held a half-day joint symposium with the HIV Clinicians Society discussing the various aspects of HIV related malignancies and how we can better co-manage these patients for improved outcomes. More local research is needed to understand the true prevalence of a co-diagnosis of HIV and cancer and in particular non-AIDS defining malignancies.[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-hiv-malignancies-symposium/ LOCATION:Movenpick Hotel\, Nairobi CATEGORIES:CME 2019,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190328T000000 DTEND;TZID=Africa/Nairobi:20190328T235959 DTSTAMP:20260424T235428 CREATED:20210421T195426Z LAST-MODIFIED:20250622T142510Z UID:4784-1553731200-1553817599@kesho-kenya.org SUMMARY:Topic: Acute Leukaemia DESCRIPTION:[vc_row][vc_column][vc_column_text] \nProf. Nicholas Abinya Medical Oncologist and Dr. Anne Mwirigi Haematologist gave stimulating perspectives on their care of patients with AML in a public versus a private setting. This led to discussions on collaborations on improving standards of care in our country and in particular with regards to supportive care and financing. KESHO is now engaging with NHIF and the NCCP to outline a treatment package for these patients that factor other costs apart from direct chemotherapy drugs. \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-acute-leukaemia/ LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya CATEGORIES:CME 2019,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190228T000000 DTEND;TZID=Africa/Nairobi:20190228T235959 DTSTAMP:20260424T235428 CREATED:20210421T200249Z LAST-MODIFIED:20250622T142510Z UID:4786-1551312000-1551398399@kesho-kenya.org SUMMARY:Topic: Updates on Recently Launched Cancer Screening Guidelines DESCRIPTION:[vc_row][vc_column][vc_column_text]In line with the launch of the Kenya Cancer Screening guidelines\, Dr Andrew Odhiambo Medical Oncologist and Dr Primus Ochieng Clinical Oncologist presented on their perspectives on the new guidelines and their experience in other settings outside of Kenya. The Screening Guidelines is as shown below: \n\n\n\n PDF Loading...\n \n \n \n \n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-updates-on-recently-launched-cancer-screening-guidelines/ CATEGORIES:CME 2019,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190131T000000 DTEND;TZID=Africa/Nairobi:20190131T235959 DTSTAMP:20260424T235428 CREATED:20210421T200621Z LAST-MODIFIED:20250622T142510Z UID:4791-1548892800-1548979199@kesho-kenya.org SUMMARY:Topic: Updates in Breast Cancer Management DESCRIPTION:[vc_row][vc_column][vc_column_text] \nWe started off the year discussing the most common cancer in women in Kenya and worldwide with two presentations. Dr Miriam Mutebi Surgical Oncologist gave an update on the surgical techniques of breast cancer management and Dr Njoki Njiriani Clinical Oncologist talking on new therapies for advanced hormone positive breast cancer \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-updates-in-breast-cancer-management/ LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya CATEGORIES:CME 2019,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20181115T000000 DTEND;TZID=Africa/Nairobi:20181117T235959 DTSTAMP:20260424T235428 CREATED:20210417T030439Z LAST-MODIFIED:20220303T081251Z UID:4661-1542240000-1542499199@kesho-kenya.org SUMMARY:The 5th Kenya International Cancer Conference DESCRIPTION:[vc_row][vc_column] \n \n Theme: Integrating Research and Practice \n \n \n [vc_tta_accordion][vc_tta_section title=”Executive Summary” tab_id=”1618600243140-acca4fba-be671a3a-4f3f”][vc_column_text]The latest cancer statistics show that the cancer burden is expected to rise to 18.1million new cases and 9.6million cancer deaths in 2018 globally. Kenya has less than 30 cancer specialists mostly in the urban settings against an increasing cancer population currently documented at 43\,000 patients across the country illuminating a dire professional deficit and much needed concerted effort by all players to curb the catastrophic effects of cancer burden. \nCancer control research therefore seeks to identify and evaluate means of reducing cancer morbidity and mortality and thereby improving the quality of life of people living with\, recovering from or dying of cancer. Knowledge of the facts and statistics\, plausible risk factors of disease and emergent complexes\, suitable interventions in response as well as the policies and frameworks that help facilitate cancer control is essential in reducing incidents\, rates and mortality due to cancer. Through research\, cancer experts are able to tackle cancer with community and country/region specific interventions. \nThe 5th International Cancer Conference in 2018 by KESHO hosted in partnership with the Ministry of Health\, Kenya\, brought together an average of more than 250 participants each conference day. They comprised both delegates and partners whose profile ranged from oncologists\, radiologists\, pharmacists\, medical officers and a myriad of players in cancer management and treatment including health authorities and experts from the state\, non-governmental organizations and projects working in screening and surveillance of risk and crisis management as well as scientists\, advocacy groups and individuals/persons living with cancer to discuss integrating cancer treatment practice and research. More than30% of the participants\, were doctors with the rest being diverse practitioners mitigating cancer related complexes. It was an opportunity to review and evaluate performance and discuss various advances made so far in cancer treatment and management both locally and globally and how to embrace them as well as create a platform to decentralize cancer information from few experts to devolved layers in cancer management such as general physicians and caregivers at county level. The program included diverse content from renowned experts in several related fields and a well versed keynote speaker from around the world and local clinical specialists and practitioners in research\, policy makers and cancer advocates to infuse a more holistic perspective. \nThe conference format included plenary sessions\, context specific breakout sessions\, illustrative exhibitions by sector players\, workshops including research workshop facilitated by international and local researchers who steer participants in navigating the enormous dilemma in conducting research (quantitative and qualitative)\, grant writing and getting published and the first ever KESHO-ASCO Joint Symposium showcasing KESHO members and ASCO faculty tackling cases in the setting of precision medicine and immunotherapy. Additionally\, there were social activities linked and tilted to the conference activities and themes such as a Gala Dinner by Texas Cancer Centre in Kenya enriched by a fashion show with cancer survivor runway models and a Cancer awareness concert by renowned celebrity artists. \nThe theme of the conference in 2018 was ‘Integrating Research and Practice’ with the main objective being to highlight the research work centred on cancer treatment and management and create a platform for local\, regional and international health care providers to present their work\, hear from each other\, learn and encourage collaboration.[/vc_column_text][/vc_tta_section][vc_tta_section title=”Sponsors” tab_id=”1618600243182-22e4f313-bf2f1a3a-4f3f”][vc_images_carousel images=”4559\,4560\,4561\,4664\,4648\,4645\,4698″ img_size=”full” onclick=”link_no” slides_per_view=”5″ wrap=”yes”][/vc_tta_section][vc_tta_section title=”Exhibitors” tab_id=”1618600981491-a82fabd7-47e61a3a-4f3f”][vc_column_text]The following were the exhibitors who participated in this conference:[/vc_column_text][vc_row_inner][vc_column_inner width=”1/3″][vc_column_text] \n\nLancet\nBayer\nMetropolis\nSalama Pharmaceuticals\nSANOFI\nSUN Pharma\n\n[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/3″][vc_column_text] \n\nMERCK\nORIGENS Limited\nF&S Scientific\nCipla\nEldoret oncology\nMercury Healthcare solutions\n\n[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/3″][vc_column_text] \n\nApollo Hospitals\nLABIOFAM\nMSN\nHETERO Mylan\nIntas Pharmaceuticals Ltd\n\n[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_tta_section][vc_tta_section title=”Attendance” tab_id=”1618602681315-0331dd50-f46e1a3a-4f3f”][vc_row_inner][vc_column_inner][vc_column_text]The 5th International Cancer Conference in 2018 by KESHO hosted in partnership with the Ministry of Health\, Kenya\, brought together more than 200 participants that comprised both delegates and partners and a myriad of players in cancer management and treatment including health authorities and experts from the state\, non-governmental organizations and projects working in screening and surveillance of risk and crisis management as well as scientists\, advocacy groups and individuals/persons living with cancer to discuss integrating cancer treatment practice and research. This year over 90 of the participants were doctors with the rest being diverse practitioners mitigating cancer related complexes. The program included diverse content from renowned experts in several related fields\, key note speakers from around the world and local clinical specialists and practitioners in research\, policy makers and cancer advocates to infuse a more holistic perspective. The attendance for the 5th International Cancer Conference in 2018 by KESHO was as follows:[/vc_column_text][vc_round_chart type=”doughnut” style=”custom” stroke_width=”2″ values=”%5B%7B%22title%22%3A%22Nurses%20and%20Support%20Staff%22%2C%22value%22%3A%2233%22%2C%22color%22%3A%22orange%22%2C%22custom_color%22%3A%22%238224e3%22%7D%2C%7B%22title%22%3A%22Local%20Doctors%20and%20Physicians%22%2C%22value%22%3A%2239%22%2C%22color%22%3A%22purple%22%2C%22custom_color%22%3A%22%23dd9933%22%7D%2C%7B%22title%22%3A%22Students%22%2C%22value%22%3A%229%22%2C%22color%22%3A%22pink%22%2C%22custom_color%22%3A%22%2381d742%22%7D%2C%7B%22title%22%3A%22Regional%20and%20International%20Delegates%22%2C%22value%22%3A%2219%22%2C%22color%22%3A%22green%22%2C%22custom_color%22%3A%22%23dd3333%22%7D%5D” css_animation=”bounceInDown”][/vc_column_inner][/vc_row_inner][/vc_tta_section][vc_tta_section title=”Program” tab_id=”1618603042055-86340cec-10511a3a-4f3f”][vc_column_text]The programme for the 5th Kenya International Cancer Conference 2018. \n\n\n\n PDF Loading...\n \n \n \n \n\n[/vc_column_text][/vc_tta_section][vc_tta_section title=”Resources” tab_id=”1618603068054-1a862002-c1861a3a-4f3f”][vc_row_inner][vc_column_inner][vc_column_text]The programme for the 5th Kenya International Cancer Conference 2018.[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_row_inner][vc_column_inner width=”1/2″][vc_column_text]\n\n\n PDF Loading...\n \n \n \n \n\n[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/2″][vc_column_text]\n\n\n PDF Loading...\n \n \n \n \n\n[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_tta_section][vc_tta_section title=”Photos” tab_id=”1618603088222-d75bc43c-cc851a3a-4f3f”][vc_row_inner][vc_column_inner][vc_column_text]View photos of the 2018 conference here[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_tta_section][/vc_tta_accordion][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/the-5th-kenya-international-cancer-conference/ LOCATION:Crowne Plaza\, Nairobi\, Kenya.\, Kenya CATEGORIES:Conferences END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20161124T000000 DTEND;TZID=Africa/Nairobi:20161126T235959 DTSTAMP:20260424T235428 CREATED:20210417T015953Z LAST-MODIFIED:20220303T081150Z UID:4640-1479945600-1480204799@kesho-kenya.org SUMMARY:The 4th Kenya International Cancer Conference DESCRIPTION:[vc_row][vc_column] \n \n Theme: Taking Cancer Care to the Community \n \n \n [vc_tta_accordion][vc_tta_section title=”Executive Summary” tab_id=”1618600243140-acca4fba-be67ab7b-49cb”][vc_column_text]In partnership with Maseno university\, KESHO hosted its 4th International Cancer Conference this time in Kisumu\, Kenya. The 2016 Conference brought together oncologists and other healthcare professionals involved in or with an interest in cancer\, cancer advocacy groups\, healthcare policy and financing agencies to present on the following topics: \nCancer prevention\, screening\, early detection\n\nThe fight against cancer – Screening\, prevention and treatment.\nEnvironmental protection in cancer prevention.\nDiet\, lifestyle and cancer\n\nCancer Epidemiology and Diagnostics\n\nBurkitt’s lymphoma and the Eastern African ecosystem.\nCancer epidemiology in East Africa – the Lake Victoria plateau and the Indian Ocean coastal lowlands.\nManagement of HIV/AIDS-related cancers\nRole of PET/CT in cancer management.\nHow can we leap frog technology for cancer diagnosis in sub-Saharan Africa?\n\nPalliative Care\n\nEstablishment of palliative care centres in Eastern Africa – Challenges and Successes.\nHow to strengthen multidisciplinary cancer care in sub-Saharan Africa.\nEstablishing networks for cancer care and research in sub-Saharan Africa\nThe role of spirituality in cancer care: The pros and cons.\nCommunicating/breaking bad news/telling the diagnosis.\n\nCancer Control Planning\n\nEstablishment of comprehensive cancer care including high dose chemotherapy in sub-Saharan Africa – the hurdles and prospects.\nChallenges in increasing radiotherapy facilities in sub-Saharan Africa.\nEstablishment of County cancer care.\nCapacity building for cancer care in Eastern Africa.\nWhere is sub-Saharan Africa in in the era of personalized cancer therapy?\nAccess to cancer care in sub-Saharan Africa: The challenges and bottlenecks; the prospects.\nRole of Ministries of Health in Africa in Cancer Care.\nChallenges of alternative Cancer care; to integrate or not to integrate with conventional care?\nExponential Growth of the Medical Tourism Industry: Curse or Blessing?\n\nThe conference saw in attendance over 200 participants from 8 different countries around the world.[/vc_column_text][/vc_tta_section][vc_tta_section title=”Sponsors” tab_id=”1618600243182-22e4f313-bf2fab7b-49cb”][vc_images_carousel images=”4558\,4559\,4560\,4561\,4645\,4646\,4648″ img_size=”full” onclick=”link_no” slides_per_view=”6″ wrap=”yes”][/vc_tta_section][vc_tta_section title=”Exhibitors” tab_id=”1618600981491-a82fabd7-47e6ab7b-49cb”][vc_column_text]Twenty four exhibitors participated in this conference.[/vc_column_text][vc_row_inner][vc_column_inner width=”1/3″][vc_column_text] \n\nTakeda\nCancer Alliance\nTCC\nBBMRI-ERIC\nAmpath Oncology\nGE\nLancet\nNairobi Hospital\n\n[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/3″][vc_column_text] \n\nAcino Switzerland\nUwezo\nBelaire\nAlexandria\nEli Lilly\nHenzo\nMedserv\nNovartis\n\n[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/3″][vc_column_text] \n\nSalama Pharmacy\nMax Foundation\nGenerics Africa\nJanssen Kenya\nSunpar Pharma\nApollo Hospital\nBecton Dickinson\nKNH\n\n[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_tta_section][vc_tta_section title=”Attendance” tab_id=”1618602681315-0331dd50-f46eab7b-49cb”][vc_row_inner][vc_column_inner][vc_column_text]A total of 187 registered for the conference\, 158 attended. Twelve (12) international delegates attended the conference. See % attendance in the below chart.[/vc_column_text][vc_round_chart type=”doughnut” style=”custom” stroke_width=”2″ values=”%5B%7B%22title%22%3A%22Nurses%20and%20Support%20Staff%22%2C%22value%22%3A%2231%22%2C%22color%22%3A%22orange%22%2C%22custom_color%22%3A%22%239900cc%22%7D%2C%7B%22title%22%3A%22Local%20Doctors%20and%20Physicians%22%2C%22value%22%3A%2249%22%2C%22color%22%3A%22purple%22%2C%22custom_color%22%3A%22%23ff9900%22%7D%2C%7B%22title%22%3A%22Students%22%2C%22value%22%3A%226%22%2C%22color%22%3A%22pink%22%2C%22custom_color%22%3A%22%23009933%22%7D%2C%7B%22title%22%3A%22Regional%20and%20International%20Delegates%22%2C%22value%22%3A%2214%22%2C%22color%22%3A%22green%22%2C%22custom_color%22%3A%22%23993333%22%7D%5D” css_animation=”bounceInDown”][/vc_column_inner][/vc_row_inner][/vc_tta_section][vc_tta_section title=”Program” tab_id=”1618603042055-86340cec-1051ab7b-49cb”][vc_column_text]Find below the programme for the 4th Kenya International Cancer Conference 2016. \n\n\n\n PDF Loading...\n \n \n \n \n\n[/vc_column_text][/vc_tta_section][vc_tta_section title=”Resources” tab_id=”1618603068054-1a862002-c186ab7b-49cb”][vc_row_inner][vc_column_inner][vc_column_text]Find below the report for the 4th Kenya International Cancer Conference 2016.[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_row_inner][vc_column_inner width=”1/2″][vc_column_text]\n\n\n PDF Loading...\n \n \n \n \n\n[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/2″][vc_column_text]\n\n\n PDF Loading...\n \n \n \n \n\n[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_tta_section][vc_tta_section title=”Photos” tab_id=”1618603088222-d75bc43c-cc85ab7b-49cb”][vc_row_inner][vc_column_inner][vc_column_text]View 2014 conference photos[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_tta_section][/vc_tta_accordion][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/the-4th-kenya-international-cancer-conference/ LOCATION:Acacia Premier\, Kisumu\, Kenya.\, Kenya CATEGORIES:Conferences END:VEVENT END:VCALENDAR